Lack of Synergistic Effect of Molsidomine and Sildenafil on Development of Pulmonary Hypertension in Chronic Hypoxic Rats
Overview
Affiliations
The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats. Two weeks of hypoxia increased right ventricular systolic pressure, and right ventricular and lung weight. Treatment with either sildenafil (10 mg/kg/day) or molsidomine (15 mg/kg/day) in drinking water reduced right ventricular systolic pressure and weight, while lung weight was unchanged. Combining sildenafil and molsidomine did not have additional effects compared to molsidomine alone. The number of muscularized pulmonary arteries with diameters below 50 microm was increased in vehicle and sildenafil-treated, but not in molsidomine-treated hypoxic rats. Acetylcholine relaxation was blunted in arteries from vehicle and molsidomine-treated, but not in sildenafil-treated rats. In conclusion, both sildenafil and molsidomine blunts pulmonary hypertension and right ventricular hypertrophy in chronic hypoxic rats, but no synergistic effects were observed.
Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension.
Reinero M, Beghetti M, Tozzi P, von Segesser L, Samaja M, Milano G J Cardiovasc Pharmacol Ther. 2021; 26(6):665-676.
PMID: 33969747 PMC: 8547238. DOI: 10.1177/10742484211014162.
Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats.
Laursen M, Beck L, Kehler J, Tornby Christoffersen C, Bundgaard C, Mogensen S Br J Pharmacol. 2017; 174(15):2563-2575.
PMID: 28548283 PMC: 5513860. DOI: 10.1111/bph.13868.
Lu W, Ran P, Zhang D, Peng G, Li B, Zhong N Am J Physiol Cell Physiol. 2009; 298(1):C114-23.
PMID: 19889962 PMC: 2806156. DOI: 10.1152/ajpcell.00629.2008.
Li N, Dai D, Dai Y Naunyn Schmiedebergs Arch Pharmacol. 2008; 378(5):541-52.
PMID: 18548232 DOI: 10.1007/s00210-008-0309-4.